Evidence Report: Parkinson’s Disease, Multiple Sclerosis, and Commercial Motor Vehicle Driver Safety (Comprehensive Review)

The purpose of this evidence report is to address several key questions posed by the Federal Motor Carrier Safety Administration (FMCSA). Each of these key questions was developed by the FMCSA such that the answers to these questions provided information that would be useful in updating its current medical examination guidelines. The five key questions addressed in this evidence report are as follows: Key Question 1: What are the criteria that define when an individual with Parkinson’s disease (PD) should stop driving a CMV? Key Question 2: What is the impact of pharmacotherapy for PD on driver safety? Key Question 3: Are individuals with multiple sclerosis (MS) at an increased risk for a motor vehicle crash? If so, what factors associated with MS are predictive of an increased crash risk? Key Question 4: How frequently should individuals with MS be assessed in order to monitor whether they remain safe to drive? Key Question 5: What is the impact of pharmacotherapy for MS on driver safety?

  • Record URL:
  • Corporate Authors:

    MANILA Consulting Group, Incorporated

    1420 Beverly Road, Suite 220
    McLean, VA  United States  22101

    ECRI Institute

    5200 Butler Pike
    Plymouth Meeting, PA  United States  19462

    Federal Motor Carrier Safety Administration

    1200 New Jersey Avenue, SE
    Washington, DC  United States  20590
  • Authors:
    • Reston, James T
    • Reed, Monica
    • Swanson, Susan
    • Tregear, Stephen
  • Publication Date: 2009-6-3


  • English

Media Info

  • Media Type: Web
  • Features: Appendices; Bibliography; Figures; Maps; Tables;
  • Pagination: 165p

Subject/Index Terms

Filing Info

  • Accession Number: 01140984
  • Record Type: Publication
  • Files: NTL, TRIS, USDOT
  • Created Date: Sep 30 2009 7:52AM